166 related articles for article (PubMed ID: 20354780)
41. Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Sasaki H; Kotsuji F; Tsang BK
Gynecol Oncol; 2002 May; 85(2):339-50. PubMed ID: 11972398
[TBL] [Abstract][Full Text] [Related]
42. [Role of focal adhesion kinase in adhesion and migration of Hep G2 cells].
Ma Y; Shen Y; Ren H; Sun H; Yu H; Lin X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Apr; 30(2):342-6, 354. PubMed ID: 23858760
[TBL] [Abstract][Full Text] [Related]
43. Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2.
Khare S; Holgren C; Samarel AM
Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1100-12. PubMed ID: 16920701
[TBL] [Abstract][Full Text] [Related]
44. Low-level shear stress promotes migration of liver cancer stem cells via the FAK-ERK1/2 signalling pathway.
Sun J; Luo Q; Liu L; Song G
Cancer Lett; 2018 Jul; 427():1-8. PubMed ID: 29678550
[TBL] [Abstract][Full Text] [Related]
45. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Slack JK; Adams RB; Rovin JD; Bissonette EA; Stoker CE; Parsons JT
Oncogene; 2001 Mar; 20(10):1152-63. PubMed ID: 11313859
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
[TBL] [Abstract][Full Text] [Related]
47. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
[TBL] [Abstract][Full Text] [Related]
48. Somatic mutational analysis of FAK in breast cancer: a novel gain-of-function mutation due to deletion of exon 33.
Fang XQ; Liu XF; Yao L; Chen CQ; Gu ZD; Ni PH; Zheng XM; Fan QS
Biochem Biophys Res Commun; 2014 Jan; 443(2):363-9. PubMed ID: 24360952
[TBL] [Abstract][Full Text] [Related]
49. Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.
Al-Ghabkari A; Qasrawi DO; Alshehri M; Narendran A
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1461-1469. PubMed ID: 31006845
[TBL] [Abstract][Full Text] [Related]
50. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
[TBL] [Abstract][Full Text] [Related]
51. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
[TBL] [Abstract][Full Text] [Related]
53. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Zhao X; Sun W; Puszyk WM; Wallet S; Hochwald S; Robertson K; Liu C
Tumour Biol; 2017 May; 39(5):1010428317699120. PubMed ID: 28459212
[TBL] [Abstract][Full Text] [Related]
54. PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation.
Mabeta P
Acta Pharm; 2016 Sep; 66(3):399-410. PubMed ID: 27383888
[TBL] [Abstract][Full Text] [Related]
55. A novel inhibitor, 16-hydroxy-cleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking.
Thiyagarajan V; Lin SH; Chia YC; Weng CF
Biochim Biophys Acta; 2013 Aug; 1830(8):4091-101. PubMed ID: 23628706
[TBL] [Abstract][Full Text] [Related]
56. ZINC40099027 activates human focal adhesion kinase by accelerating the enzymatic activity of the FAK kinase domain.
Rashmi ; More SK; Wang Q; Vomhof-DeKrey EE; Porter JE; Basson MD
Pharmacol Res Perspect; 2021 Apr; 9(2):e00737. PubMed ID: 33715263
[TBL] [Abstract][Full Text] [Related]
57. FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.
Heffler M; Golubovskaya VM; Conroy J; Liu S; Wang D; Cance WG; Dunn KB
Anticancer Agents Med Chem; 2013 May; 13(4):584-94. PubMed ID: 22934709
[TBL] [Abstract][Full Text] [Related]
58. Focal adhesion kinase (FAK) and mechanical stimulation negatively regulate the transition of airway smooth muscle tissues to a synthetic phenotype.
Wu Y; Huang Y; Gunst SJ
Am J Physiol Lung Cell Mol Physiol; 2016 Nov; 311(5):L893-L902. PubMed ID: 27612967
[TBL] [Abstract][Full Text] [Related]
59. Inhibiting focal adhesion kinase (FAK) blocks IL-4 induced VCAM-1 expression and eosinophil recruitment in vitro and in vivo.
Aulakh GK; Petri B; Wojcik KM; Colarusso P; Lee JJ; Patel KD
J Leukoc Biol; 2018 Jul; 104(1):147-158. PubMed ID: 29633338
[TBL] [Abstract][Full Text] [Related]
60. Tyrosine 397 phosphorylation is critical for FAK-promoted Rac1 activation and invasive properties in oral squamous cell carcinoma cells.
Chiu YW; Liou LY; Chen PT; Huang CM; Luo FJ; Hsu YK; Yuan TC
Lab Invest; 2016 Mar; 96(3):296-306. PubMed ID: 26752742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
